Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy.

Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy.

The present disclosure relates generally to consumable electrolyte compositions, and more specifically to such compositions that contain high concentrations of potassium for alleviation of muscle cramping.

The present disclosure relates generally to consumable electrolyte compositions, and more specifically to such compositions that contain high concentrations of potassium for alleviation of muscle cramping.

Embodiments disclosed relate to a nutritional formula having non-fat milk powder, lactose, an oil blend, enriched whey protein concentrate, oligosaccharides, choline, arachidonic acid (ACA), docosahexaenoic acid (DHA), magnesium oxide, sodium citrate, lactoferrin, inositol, taurine, iron, L-carnitine, zinc, nucleotides, soy lecithin, pantothenic acid, copper, D-biotin, folic acid, lutein, manganese sulfate, iodine, Beta-carotene, and selenium, and to methods of delivering nutrition to a subject.

Embodiments disclosed relate to a nutritional formula having non-fat milk powder, lactose, an oil blend, enriched whey protein concentrate, oligosaccharides, choline, arachidonic acid (ACA), docosahexaenoic acid (DHA), magnesium oxide, sodium citrate, lactoferrin, inositol, taurine, iron, L-carnitine, zinc, nucleotides, soy lecithin, pantothenic acid, copper, D-biotin, folic acid, lutein, manganese sulfate, iodine, Beta-carotene, and selenium, and to methods of delivering nutrition to a subject.

The present disclosure encompasses a non-caking, free-flowing composition comprising choline chloride.

The present disclosure encompasses a non-caking, free-flowing composition comprising choline chloride.

The present invention pertains to the field of oral electrolyte solutions (OES), particularly OES for calves. Particularly the present invention is in the fields of reducing diarrhea, reducing body weight loss, reducing fecal water loss and/or improving blood acid-base balance in a calf suffering from diarrhea.

The present invention pertains to the field of oral electrolyte solutions (OES), particularly OES for calves. Particularly the present invention is in the fields of reducing diarrhea, reducing body weight loss, reducing fecal water loss and/or improving blood acid-base balance in a calf suffering from diarrhea.